Role of training dose in drug discrimination: a review

被引:46
作者
Stolerman, Ian P. [1 ]
Childs, Emma [2 ]
Ford, Matthew M. [3 ]
Grant, Kathleen A. [3 ]
机构
[1] Kings Coll London, Inst Psychiat, Dept Addict, London WC2R 2LS, England
[2] Univ Chicago, Dept Psychiat, Chicago, IL 60637 USA
[3] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA
来源
BEHAVIOURAL PHARMACOLOGY | 2011年 / 22卷 / 5-6期
基金
美国国家卫生研究院;
关键词
cannabinoids; drug discrimination; ethanol; gamma-aminobutyric acid mimetics; hallucinogens; nicotine; opioids; psychomotor stimulants; review; GAMMA-HYDROXYBUTYRIC ACID; STIMULUS PROPERTIES; RECEPTOR LIGANDS; NICOTINE DISCRIMINATION; INTRINSIC EFFICACY; CUE SENSITIVITY; RESPONSE RATE; TIME-COURSE; MU OPIOIDS; PHARMACOLOGICAL CHARACTERIZATION;
D O I
10.1097/FBP.0b013e328349ab37
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Drug discrimination has been an important technique in behavioural pharmacology for at least 40 years. The characteristics of drug-produced discriminative stimuli are influenced by behavioural and pharmacological variables, including the doses used to establish discriminations. This review covers studies on the effects of varying the training dose of a drug in a search for general principles that are applicable across different drug classes and methodological approaches. With respect to quantitative changes, relationships between training dose and the rate of acquisition or magnitude of stimulus control were found for most drug classes. Acquisition accelerated with dose up to a point beyond which drug-induced impairments of performance had a deleterious impact. Sensitivity to the training drug as measured by ED50 values typically increased when the training dose was reduced. Qualitative changes were more complex and appeared to fall into three categories: (a) changes in profiles of generalization between partial and full agonists; (b) reduced specificity of some discriminations at small training doses; and (c) changes in the relative salience of actions mediated through different neurotransmitter systems or from central and peripheral sites. Three-lever discrimination procedures incorporating 'drug versus drug' or 'dose versus dose' contingencies enabled detection of more subtle differences than the simple 'drug versus no drug' approach when applied to the opioid, hallucinogen and barbiturate classes of drugs. These conclusions have implications for the interpretation of data from studies that use either within-subject or between-subject designs for studying the discriminative stimulus effects of drugs. Behavioural Pharmacology 22:415-429 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:415 / 429
页数:15
相关论文
共 158 条
[1]  
ATOR NA, 1991, BEHAV PHARMACOL, V2, P3
[2]   DIFFERENTIAL GENERALIZATION TO PENTOBARBITAL IN RATS TRAINED TO DISCRIMINATE LORAZEPAM, CHLORDIAZEPOXIDE, DIAZEPAM, OR TRIAZOLAM [J].
ATOR, NA ;
GRIFFITHS, RR .
PSYCHOPHARMACOLOGY, 1989, 98 (01) :20-30
[3]   DRUG DISCRIMINATION IN RATS - EVIDENCE FOR AMPHETAMINE-LIKE CUE STATE FOLLOWING CHRONIC HALOPERIDOL [J].
BARRETT, RJ ;
STERANKA, LR .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1983, 18 (04) :611-617
[4]   Attenuation of nicotine's discriminative stimulus effects in rats and its locomotor activity effects in mice by serotonergic 5-HT2A/2C receptor agonists [J].
Batman, AM ;
Munzar, P ;
Beardsley, PM .
PSYCHOPHARMACOLOGY, 2005, 179 (02) :393-401
[5]  
BEARDSLEY PM, 1987, J PHARMACOL EXP THER, V241, P159
[6]  
BEARDSLEY PM, 1988, J PHARMACOL EXP THER, V244, P34
[7]   Behavioral and biochemical investigations of bupropion metabolites [J].
Bondarev, ML ;
Bondareva, TS ;
Young, R ;
Glennon, RA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 474 (01) :85-93
[8]  
Bowen CA, 1999, J PHARMACOL EXP THER, V289, P405
[9]   An investigation of endogenous neuroactive steroid-induced modulation of ethanol's discriminative stimulus effects [J].
Bowen, CA ;
Purdy, RH ;
Grant, KA .
BEHAVIOURAL PHARMACOLOGY, 1999, 10 (03) :297-311
[10]   The discriminative stimulus properties of U50,488 and morphine are not shared by fedotozine [J].
Broqua, P ;
Wettstein, JG ;
Rocher, MN ;
Rivière, PJM ;
Dahl, SG .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1998, 8 (04) :261-266